Enanta Pharmaceuticals appoints Nathalie Adda chief medical officer
Enanta Pharmaceuticals, a R&D-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has appointed Nathalie Adda, M.D., senior vice president and chief medical officer, responsible for clinical and regulatory affairs.
Adda is a specialist in infectious disease and has more than 15 years of experience in the pharmaceutical industry in all phases of global clinical research and development and commercialization.
Most recently, Adda was chief medical officer, vice president clinical development, medical and regulatory affairs at Transgene, where she led the oncology and infectious disease programs since 2012. From 2006 to 2012, she was senior medical director and the medical lead for the Incivek (telaprevir) clinical program at Vertex Pharmaceuticals, where she designed the phase II and phase III programs, and led the medical team in its successful marketing applications and registration in the U.S., Canada and Asia.
Earlier in her career, she held medical and research positions at Gilead, Triangle Pharmaceuticals and Boehringer Ingelheim, where she worked on programs for infectious diseases such as human immunodeficiency virus, hepatitis B virus and hepatitis C virus.